MedPath

CB1R in Synthetic Psychoactive Cannabinoids

Not Applicable
Active, not recruiting
Conditions
Drug Dependence
Interventions
Other: [11-C]OMAR
Registration Number
NCT03539575
Lead Sponsor
Yale University
Brief Summary

The purpose of this research study is to determine whether the CB1R availability is lower in synthetic psychoactive cannabinoid subjects using the most widely available synthetic psychoactive cannabinoids at the time the study is initiated.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
15
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Synthetic Psychoactive Cannabinoid Users[11-C]OMARSynthetic Psychoactive Cannabinoid dependent subjects who are frequent spice/K2 users will receive the radiotracer \[11-C\]OMAR.
Primary Outcome Measures
NameTimeMethod
Positron Emission Tomography (PET Imaging)Change in CB1R availability from baseline throughout one test day

CB1R availability using \[11-C\]OMAR PET imaging Change in CB1R availability (e.g. volume distribution).

Secondary Outcome Measures
NameTimeMethod
CogState BatteryChange in CB1R availability from baseline throughout one test day

2. Changes in Cognition during withdrawal using a computerized battery Changes in cognitive functions such as attention, memory, motor functioning, and processing speed.

ElectroencephalogramChange in CB1R availability from baseline throughout one test day

3. Changes in brain rhythms measured by Electroencephalography Changes in electroencephalographic (EEG) brain rhythms related to information processing.

Trial Locations

Locations (1)

Connecticut Mental Health Center

🇺🇸

New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath